Document is current
Any future updates will be listed below
-
Authors
Aydin, Ahmet Murat https://orcid.org/0000-0002-6047-8431
Chahoud, Jad
Adashek, Jacob J. https://orcid.org/0000-0003-4272-312X
Azizi, Mounsif
Magliocco, Anthony
Ross, Jeffrey S.
Necchi, Andrea
Spiess, Philippe E. https://orcid.org/0000-0002-5723-1972
- License Information
-
More Information
Article History
Accepted: 3 July 2020
First Online: 18 August 2020
Competing interests
: J.S.R.: employment: Foundation Medicine; leadership: Foundation Medicine; stock and other ownership interests: Foundation Medicine; research funding: Foundation Medicine. A.N.: employment: Bayer A.G.; stock and other ownership interests: Bayer A.G.; honoraria: Roche Merck, AstraZeneca, Janssen Pharmaceuticals, and Foundation Medicine; consulting or advisory role: Merck Sharp & Dohme, Roche, Bayer A.G., AstraZeneca, Clovis Oncology, Janssen Pharmaceuticals, Incyte, Seattle Genetics, Astellas Pharma, Bristol-Myers Squibb and Rainier Therapeutics; research funding: Merck Sharp & Dohme (to the institute) and AstraZeneca (to the institute); travel, accommodations, expenses: Roche, Merck Sharp & Dohme, AstraZeneca and Janssen Pharmaceuticals. P.E.S.: consulting or advisory role: Genentech and Pfizer. A.M.A., J.C., J.J.A., M.A. and A.M. declare no competing interests.
